兰地洛尔临床应用中国专家共识  

Chinese Expert Consensus on the Clinical Application of Landiolol

作　　者：中国医师协会心力衰竭专业委员会 国家心血管病专家委员会心力衰竭专业委员会 中华心力衰竭和心肌病杂志编委会 张宇辉 翟玫 韩凌 白玲[3] 张瑶 Chinese Heart Failure Association of Chinese Medical Doctor Association;National Expert Committee on Cardiovascular Diseases and Professional Committee on Heart Failure;Editorial Board of Chinese Journal of Heart Failure and Cardiomyopathy;Zhang yuhui

机构地区：[1]不详 [2]中国医学科学院阜外医院 [3]西安交通大学第一附属医院 [4]哈尔滨医科大学附属第二医院

出　　处：《中华心力衰竭和心肌病杂志（中英文）》2021年第2期85-90,共6页Chinese Journal of Heart Failure and Cardiomyopathy

摘　　要：兰地洛尔是新一代速效、超短效、高选择性β_(1)受体阻滞剂,对心脏抑制作用弱且较少引起低血压。国内医师对兰地洛尔的认识和用药经验相对匮乏。为使临床医师更充分了解和合理使用兰地洛尔,中国医师协会心力衰竭专业委员会组织国内该领域专家制定了本共识。本共识从兰地洛尔的药代动力学和药理作用,以及在快速心律失常、急性冠状动脉综合征、急性失代偿性心力衰竭、围术期综合应用、严重脓毒症/脓毒性休克等方面的临床应用做以详尽阐述,旨在指导临床医师合理、规范用药。Landilol is a new generation of fast acting,ultra-short acting and highly selective β_(1) receptor blocker;which has weak cardiac inhibition and less hypotension.Domestic doctors are relatively short of knowledge and experience on landilol.In order to enable clinicians to fully understand and rationally use landiolol,the Chinese Heart Failure Association of the Chinese Medical Doctor Association organized domestic experts in this field to formulate this consensus.This consensus will introduce the pharmacokinetics and pharmacological effects of landiolol,and elaborate the clinical application of landiolol in tachyarrhythmia,acute coronary syndrome,acute decompensated heart failure,perioperative comprehensive application,severe sepsis/septic shock,etc,in order to guide the reasonable use of landiolol for clinical physicians.

关 键 词：静脉β肾上腺素能受体阻滞剂 兰地洛尔 

分 类 号：R971.9[医药卫生—药品]